According to Zacks, “SomaLogic Inc. provides AI-data driven proteomics technology. SomaLogic Inc., formerly known as CM Life Sciences II Inc., is based in NEW YORK. “
Separately, Stifel Nicolaus began coverage on SomaLogic in a report on Tuesday, February 1st. They issued a “buy” rating and a $12.00 target price on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $16.25.
SomaLogic (NASDAQ:SLGC – Get Rating) last issued its earnings results on Tuesday, March 29th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). On average, sell-side analysts expect that SomaLogic will post -0.69 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the business. Cinctive Capital Management LP boosted its position in SomaLogic by 1.8% during the fourth quarter. Cinctive Capital Management LP now owns 154,758 shares of the company’s stock worth $1,801,000 after purchasing an additional 2,690 shares during the period. PNC Financial Services Group Inc. bought a new stake in shares of SomaLogic in the third quarter valued at approximately $37,000. Wolverine Asset Management LLC bought a new stake in shares of SomaLogic in the fourth quarter valued at approximately $36,000. Samlyn Capital LLC boosted its position in shares of SomaLogic by 1.0% in the fourth quarter. Samlyn Capital LLC now owns 381,070 shares of the company’s stock valued at $4,436,000 after acquiring an additional 3,815 shares during the period. Finally, Sargent Bickham Lagudis LLC bought a new stake in shares of SomaLogic in the first quarter valued at approximately $34,000. 58.65% of the stock is owned by hedge funds and other institutional investors.
About SomaLogic (Get Rating)
SomaLogic, Inc operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples.
- Get a free copy of the StockNews.com research report on SomaLogic (SLGC)
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Peak Growth Is Over For Etsy
- Uber Fails To Impress
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.